JP2021506243A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021506243A5 JP2021506243A5 JP2020531949A JP2020531949A JP2021506243A5 JP 2021506243 A5 JP2021506243 A5 JP 2021506243A5 JP 2020531949 A JP2020531949 A JP 2020531949A JP 2020531949 A JP2020531949 A JP 2020531949A JP 2021506243 A5 JP2021506243 A5 JP 2021506243A5
- Authority
- JP
- Japan
- Prior art keywords
- cell line
- immortalized
- cell
- seq
- domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762598032P | 2017-12-13 | 2017-12-13 | |
| US62/598,032 | 2017-12-13 | ||
| PCT/US2018/064971 WO2019118475A1 (en) | 2017-12-13 | 2018-12-11 | Immortalized car-t cells genetically modified to eliminate t-cell receptor and beta 2-microglobulin expression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021506243A JP2021506243A (ja) | 2021-02-22 |
| JP2021506243A5 true JP2021506243A5 (enExample) | 2022-01-11 |
Family
ID=66734891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020531949A Pending JP2021506243A (ja) | 2017-12-13 | 2018-12-11 | Ｔ細胞受容体及びβ２ミクログロブリン発現を排除するように遺伝子改変された不死化ＣＡＲ−Ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190175651A1 (enExample) |
| EP (1) | EP3724321A4 (enExample) |
| JP (1) | JP2021506243A (enExample) |
| KR (1) | KR20200088383A (enExample) |
| CN (1) | CN111479917A (enExample) |
| AU (1) | AU2018386010A1 (enExample) |
| CA (1) | CA3082204A1 (enExample) |
| SG (1) | SG11202003864XA (enExample) |
| WO (1) | WO2019118475A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
| CN105939767B (zh) | 2014-01-08 | 2018-04-06 | 弗洛设计声能学公司 | 具有双声电泳腔的声电泳装置 |
| US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
| US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
| WO2018111976A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Pd-l1 binding fibronectin type iii domains |
| WO2018111978A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
| KR102568559B1 (ko) | 2016-12-14 | 2023-08-18 | 얀센 바이오테크 인코포레이티드 | Cd8a-결합 섬유결합소 iii형 도메인 |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| JP7280238B2 (ja) * | 2017-07-17 | 2023-05-23 | ヤンセン バイオテツク，インコーポレーテツド | フィブロネクチンｉｉｉ型ドメインに対する抗原結合領域及びその使用方法 |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| TW202118792A (zh) | 2019-07-26 | 2021-05-16 | 美商健生生物科技公司 | 抗hk2嵌合抗原受體(car) |
| PH12022550548A1 (en) | 2019-09-06 | 2023-11-20 | Crispr Therapeutics Ag | Genetically engineered t cells having improved persistence in culture |
| CN114786682B (zh) | 2019-10-14 | 2024-07-16 | Aro生物疗法公司 | 结合cd71的纤维粘连蛋白iii型结构域 |
| WO2021076543A1 (en) * | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Epcam binding fibronectin type iii domains |
| US11781138B2 (en) | 2019-10-14 | 2023-10-10 | Aro Biotherapeutics Company | FN3 domain-siRNA conjugates and uses thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| GB202005216D0 (en) * | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| US11459372B2 (en) | 2020-11-30 | 2022-10-04 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
| JP2024517610A (ja) | 2021-04-14 | 2024-04-23 | アロ・バイオセラピューティクス・カンパニー | Ｃｄ７１に結合するフィブロネクチンｉｉｉ型ドメイン |
| KR20240031947A (ko) | 2021-04-14 | 2024-03-08 | 에이알오 바이오테라퓨틱스 컴패니 | Fn3 도메인-시르나 접합체 및 이의 용도 |
| US20240245722A1 (en) * | 2021-05-25 | 2024-07-25 | Vaxcell-Bio | Monobody-based chimeric antigen receptor and immune cell including same |
| CA3231670A1 (en) * | 2021-09-10 | 2023-03-16 | Kite Pharma, Inc. | Alternative generation of allogeneic human t cells |
| CN116023496B (zh) * | 2021-10-27 | 2026-02-27 | 菲鹏弘济生物(深圳)有限公司 | 一种制备通用型car-t细胞的方法及其应用 |
| US12006353B2 (en) | 2022-07-25 | 2024-06-11 | Long Chen | Application of SCFV protein, car gene expression vector, CAR-T cell and application thereof |
| JP2026506126A (ja) * | 2023-02-17 | 2026-02-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 既製の細胞療法のための多能性幹細胞操作免疫細胞 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX358827B (es) * | 2011-09-27 | 2018-09-05 | Janssen Biotech Inc | Supercóntigos de proteína basados en repeticiones de fibronectina tipo iii con superficies de unión alternativas. |
| RU2752933C2 (ru) * | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| AU2015292744C1 (en) * | 2014-07-21 | 2021-01-21 | Novartis Ag | Treatment of cancer using humanized anti-BCMA chimeric antigen receptor |
| KR102546296B1 (ko) * | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| JP7366518B2 (ja) * | 2015-05-06 | 2023-10-23 | ヤンセン バイオテツク，インコーポレーテツド | 前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン |
| US11352631B2 (en) * | 2015-12-18 | 2022-06-07 | Sangamo Therapeutics, Inc. | Targeted disruption of the T cell receptor |
| AU2016374253B2 (en) * | 2015-12-18 | 2021-10-21 | Sangamo Therapeutics, Inc. | Targeted disruption of the MHC cell receptor |
| US20190017075A1 (en) * | 2015-12-23 | 2019-01-17 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| CN109715199A (zh) * | 2016-09-14 | 2019-05-03 | 詹森生物科技公司 | 包含bcma特异性iii型纤连蛋白结构域的嵌合抗原受体及其用途 |
-
2018
- 2018-12-11 CA CA3082204A patent/CA3082204A1/en active Pending
- 2018-12-11 EP EP18888643.6A patent/EP3724321A4/en not_active Withdrawn
- 2018-12-11 SG SG11202003864XA patent/SG11202003864XA/en unknown
- 2018-12-11 KR KR1020207016631A patent/KR20200088383A/ko not_active Ceased
- 2018-12-11 CN CN201880080452.1A patent/CN111479917A/zh active Pending
- 2018-12-11 US US16/215,716 patent/US20190175651A1/en not_active Abandoned
- 2018-12-11 JP JP2020531949A patent/JP2021506243A/ja active Pending
- 2018-12-11 US US16/770,809 patent/US20200332255A1/en not_active Abandoned
- 2018-12-11 WO PCT/US2018/064971 patent/WO2019118475A1/en not_active Ceased
- 2018-12-11 AU AU2018386010A patent/AU2018386010A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Siemaszko et al. | NKG2D natural killer cell receptor—a short description and potential clinical applications | |
| JP7861191B2 (ja) | 免疫のための増強されたキメラ抗原受容体エフェクター細胞操作およびその使用 | |
| JP7783746B2 (ja) | 操作されたｉＰＳＣおよび免疫エフェクター細胞におけるＣＤ３の再構成 | |
| JP2023080187A (ja) | 増強されたキメラ抗原受容体およびその使用 | |
| CA2942113C (en) | Method for generating t-cells compatible for allogenic transplantation | |
| JP7863553B2 (ja) | 固形腫瘍を標的とする多重操作されたｉＰＳＣ及び免疫エフェクター細胞 | |
| JP2021505131A (ja) | 増強されたｉＰＳＣ由来のエフェクター細胞を用いた免疫療法 | |
| JP2021506236A (ja) | 強化された免疫エフェクター細胞およびその使用 | |
| CN114761425A (zh) | 用于免疫效应细胞工程化的增强的嵌合抗原受体和其用途 | |
| JP2021519061A (ja) | 操作された免疫エフェクター細胞およびその使用 | |
| JP2020509050A5 (enExample) | ||
| JP2017537622A5 (enExample) | ||
| JP2022512882A5 (enExample) | ||
| WO2018205926A1 (zh) | 经修饰的t细胞、其制备方法及用途 | |
| JP2018514204A5 (enExample) | ||
| JP2016534717A5 (enExample) | ||
| JP2019530431A5 (enExample) | ||
| CN114729315A (zh) | 用于提供具有增强功能的免疫细胞的方法 | |
| JP2024537991A (ja) | 共発現されるｓｈＲＮＡと論理ゲートシステムとを有する免疫細胞 | |
| BR112020020919A2 (pt) | Receptor de antígeno quimérico específico para receptor de interleucina-23 | |
| IL302476A (en) | Engineered ipsc and immune effector cells for heterogenous tumor control | |
| WO2022063302A1 (zh) | 免疫细胞活性调节 | |
| CN113631184A (zh) | 通过抑制ebag9增强溶细胞性t细胞活性 | |
| IL301983A (en) | Transgenic induced pluripotent stem cells and effector carrier cells of the immune system | |
| US20250388646A1 (en) | Enhancing effector cell durability and efficacy in adoptive cell therapies |